{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"120"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"341"}],"units":"Participants"}],"title":"Improved Cough"},{"categories":[{"measurements":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"150"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"340"}],"units":"Participants"}],"title":"Improved Dyspnoea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"134"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"343"},{"groupId":"OG001","value":"342"}],"units":"Participants"}],"title":"Improved Pain Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"339"}],"units":"Participants"}],"title":"Improved Global Health Status"}],"denoms":[{"counts":[{"groupId":"OG000","value":"398"},{"groupId":"OG001","value":"397"}],"units":"Participants"}],"description":"Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the european organization for research and treatment of cancer (eortc) quality of life questionnaire (QLQ-C30) questionnaire and its lung cancer specific supplementary module EORTC QLQ-LC13 and the EQ-5D health status self-assessment questionnaire. The questionnaires were assessed at the first visit of each treatment course, at end of treatment (EOT) and follow up prior to clinical assessment. The results displayed show number of patients with improvement in the relevant criteria. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: The number of patients that were improved: Change in cough; dyspnoea and pain scores over time.","groups":[{"description":"Patients administered 40 milligram (mg) film-coated tablet once daily orally for the first 28-day treatment course. Dose escalation to 50 mg once daily was allowed at the beginning of the second 28-day treatment course, if patients met specified safety and compliance criteria. Dose reduction to 40 mg/day (if applicable), 30 mg/day, or 20 mg/day, was required in the presence of known drug-related adverse events.","id":"OG000","title":"Afatinib"},{"description":"Patients administered 150 mg film-coated tablet once daily orally, with dose reduction to 100 mg/day or 50 mg/day in the presence of known drug-related adverse events.","id":"OG001","title":"Erlotinib"}],"paramType":"NUMBER","populationDescription":"RS","reportingStatus":"POSTED","timeFrame":"From first drug administration from 9 April 2012 until study closure on 27 Dec 2017 (approximately 2089 days).","title":"Number of Participants With Status Change in Cough, Dyspnoea and Pain Related Items Over Time in Health Related Quality of Life Questionnaire","type":"SECONDARY","unitOfMeasure":"Participants"}